Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9313102rdf:typepubmed:Citationlld:pubmed
pubmed-article:9313102lifeskim:mentionsumls-concept:C0439849lld:lifeskim
pubmed-article:9313102lifeskim:mentionsumls-concept:C0003241lld:lifeskim
pubmed-article:9313102lifeskim:mentionsumls-concept:C0039082lld:lifeskim
pubmed-article:9313102lifeskim:mentionsumls-concept:C0683325lld:lifeskim
pubmed-article:9313102pubmed:issue9lld:pubmed
pubmed-article:9313102pubmed:dateCreated1997-10-30lld:pubmed
pubmed-article:9313102pubmed:abstractTextWe studied relationships between anti-ganglioside antibodies and the clinical characteristics of Guillain-Barré syndrome (GBS) using multivariate analysis. Serum anti-ganglioside antibodies were measured by enzyme-linked immunosorbent assay (ELISA) in 42 GBS patients and 47 controls. Relationships between antibodies and 15 clinical characteristics were analyzed using a logistic model. Anti-GM1 antibodies were significantly infrequent in patients with objective sensory disturbance (immunoglobulin G (IgG), p < 0.05, odds ratio = 0.094; immunoglobulin M (IgM), p < 0.01, odds ratio = 0.032) and frequent in patients with prodromal diarrhea (IgG, p < 0.05, odds ratio = 5.759; IgM, p < 0.05, odds ratio = 16.28). The combination of anti-GM1 and anti-GD1b antibodies was frequent in patients with prodromal diarrhea (IgG, p < 0.01, odds ratio = 9.667; IgM, p < 0.01, odds ratio = 14.50). IgG anti-GQ1b antibodies were extremely frequent in patients with ophthalmoplegia (p < 0.01, odds ratio = 102.3), and infrequent in patients with objective sensory disturbance (p < 0.05, odds ratio = 0.023).lld:pubmed
pubmed-article:9313102pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9313102pubmed:languageenglld:pubmed
pubmed-article:9313102pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9313102pubmed:citationSubsetIMlld:pubmed
pubmed-article:9313102pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9313102pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9313102pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9313102pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9313102pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9313102pubmed:statusMEDLINElld:pubmed
pubmed-article:9313102pubmed:monthSeplld:pubmed
pubmed-article:9313102pubmed:issn0918-2918lld:pubmed
pubmed-article:9313102pubmed:authorpubmed-author:SaitoTTlld:pubmed
pubmed-article:9313102pubmed:authorpubmed-author:ItoHHlld:pubmed
pubmed-article:9313102pubmed:authorpubmed-author:OginoMMlld:pubmed
pubmed-article:9313102pubmed:authorpubmed-author:IrieSSlld:pubmed
pubmed-article:9313102pubmed:authorpubmed-author:KanazawaNNlld:pubmed
pubmed-article:9313102pubmed:authorpubmed-author:KowaHHlld:pubmed
pubmed-article:9313102pubmed:authorpubmed-author:NukazawaTTlld:pubmed
pubmed-article:9313102pubmed:issnTypePrintlld:pubmed
pubmed-article:9313102pubmed:volume36lld:pubmed
pubmed-article:9313102pubmed:ownerNLMlld:pubmed
pubmed-article:9313102pubmed:authorsCompleteYlld:pubmed
pubmed-article:9313102pubmed:pagination607-12lld:pubmed
pubmed-article:9313102pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9313102pubmed:meshHeadingpubmed-meshheading:9313102-...lld:pubmed
pubmed-article:9313102pubmed:meshHeadingpubmed-meshheading:9313102-...lld:pubmed
pubmed-article:9313102pubmed:meshHeadingpubmed-meshheading:9313102-...lld:pubmed
pubmed-article:9313102pubmed:meshHeadingpubmed-meshheading:9313102-...lld:pubmed
pubmed-article:9313102pubmed:meshHeadingpubmed-meshheading:9313102-...lld:pubmed
pubmed-article:9313102pubmed:meshHeadingpubmed-meshheading:9313102-...lld:pubmed
pubmed-article:9313102pubmed:meshHeadingpubmed-meshheading:9313102-...lld:pubmed
pubmed-article:9313102pubmed:meshHeadingpubmed-meshheading:9313102-...lld:pubmed
pubmed-article:9313102pubmed:meshHeadingpubmed-meshheading:9313102-...lld:pubmed
pubmed-article:9313102pubmed:meshHeadingpubmed-meshheading:9313102-...lld:pubmed
pubmed-article:9313102pubmed:meshHeadingpubmed-meshheading:9313102-...lld:pubmed
pubmed-article:9313102pubmed:meshHeadingpubmed-meshheading:9313102-...lld:pubmed
pubmed-article:9313102pubmed:meshHeadingpubmed-meshheading:9313102-...lld:pubmed
pubmed-article:9313102pubmed:meshHeadingpubmed-meshheading:9313102-...lld:pubmed
pubmed-article:9313102pubmed:meshHeadingpubmed-meshheading:9313102-...lld:pubmed
pubmed-article:9313102pubmed:year1997lld:pubmed
pubmed-article:9313102pubmed:articleTitleRelationships between anti-ganglioside antibodies and clinical characteristics of Guillain-Barré syndrome.lld:pubmed
pubmed-article:9313102pubmed:affiliationDepartment of Neurology, Kitasato University East Hospital, Sagamihara, Kanagawa.lld:pubmed
pubmed-article:9313102pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9313102pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9313102lld:pubmed